- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.12.25 | NeuroPace seeks FDA approval to expand RNS System for epilepsy treatment | 4 | Investing.com | ||
| NEUROPACE Aktie jetzt für 0€ handeln | |||||
| 03.12.25 | BDMD: Baird Medical Appoints Mark Saxton as U.S. CEO; Taps Veteran from NeuroPace, Smith + Nephew, and Covidien to Lead Commercial Expansion | 206 | PR Newswire | NEW YORK, Dec. 3, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive... ► Artikel lesen | |
| 10.11.25 | Cantor Fitzgerald bestätigt "Overweight"-Rating für NeuroPace nach starken Quartalszahlen | 3 | Investing.com Deutsch | ||
| 10.11.25 | Cantor Fitzgerald reiterates Overweight rating on NeuroPace stock | 1 | Investing.com | ||
| 05.11.25 | NeuroPace stock rises as Cantor Fitzgerald reiterates Overweight rating | 2 | Investing.com | ||
| 05.11.25 | NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down | 1 | Seeking Alpha | ||
| 04.11.25 | NeuroPace GAAP EPS of -$0.11 beats by $0.09, revenue of $27.4M beats by $2.77M | 4 | Seeking Alpha | ||
| 04.11.25 | NeuroPace Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 04.11.25 | NeuroPace Inc - 8-K, Current Report | - | SEC Filings | ||
| 09.09.25 | NeuroPace stock remains Cantor Fitzgerald's top pick for 2025 | 2 | Investing.com | ||
| 09.09.25 | NeuroPace: Cantor Fitzgerald bestätigt Aktie als Top-Pick für 2025 | 2 | Investing.com Deutsch | ||
| 14.08.25 | NeuroPace stock price target lowered to $13 by Wolfe Research | 2 | Investing.com | ||
| 14.08.25 | NeuroPace: Wolfe Research senkt Kursziel auf 13 US-Dollar, bestätigt aber "Outperform" | 1 | Investing.com Deutsch | ||
| 13.08.25 | NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth | 1 | Seeking Alpha | ||
| 12.08.25 | NeuroPace Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 01.08.25 | NeuroPace, Inc.: NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases | 436 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued... ► Artikel lesen | |
| 29.07.25 | NeuroPace, Inc.: NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025 | 3 | GlobeNewswire (USA) | ||
| 24.06.25 | NeuroPace, Inc.: NeuroPace Announces Strategic CFO Transition | 225 | GlobeNewswire (Europe) | Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory... ► Artikel lesen | |
| 27.05.25 | NeuroPace, Inc.: NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study | 437 | GlobeNewswire (Europe) | -- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study... ► Artikel lesen | |
| 14.04.25 | NeuroPace, Inc.: NeuroPace Provides Update on Tariff Status | 299 | GlobeNewswire (Europe) | -- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|
NEUROPACE INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 15,445 Euro und damit -0,16 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROPACE INC finden Sie auf Wallstreet Online.